OIPE						Sheet 1 of	f <u>2</u>			
JUL 1 0 2000 ATION PIPE OF ATTEMENT				ATTY. DOCKET N 3220-69262		SERIAL No. 10/044,031				
				APPLICANT(S): B		GROUP: 3738				
INFO	INFORMATION DISCLOSURE STATEMENT				FILING DATE: January 11, 2002					
INFO			U.S. PATENT	DOCUMENTS						
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate			
	AA									
	AB									
	AC									
	AD					,				
	AE				-					
	AF									
	AG									
	AH									
	Al									
	AJ									
	AK		·							
			FOREIGN PATE	NT DOCUMENTS						
		Document Number	Date	Country	Class	Subclass	Translation Yes No			
	AL									
	AM		-							
	AN									
	AO									
	AP									
	_		ENCES (Including A							
/PP/	AR	& Biodegradation, 30, 29-46 (1992).								
/PP/	AS	Barry N. Taylor, "Guide for the Use of the International Systems of Units (SI),"National Institute of								
/PP/	AT	Standards and Technology, Special Publication 811 (1995).  "Bacterial Endotoxins/Pyrogens," Inspector's Technical Guide, Dept. of Health, Education, and Welfare Public Health Service, Food and Drug Administration, 40, (03-20-1985).								
/PP/	AU	Abstract of Yagoda et al., "Some effects of gram-negative bacterial endotoxin and its importance as a contaminator of biological preparations," <i>Acta Vet Scand.</i> , 31(2), 193-206 (1990).								
	AV	Abstract of Tsuji et a	al., "Recovery of ende	otoxin from human p	lasma by acid	oxidative treat				
/PP/		monitored by an aut method," <i>Prog Clin</i> I	Biol Res., 231, 443-4	57 (1987). <sup>*</sup>						
/PP/	AW	Abstract of Burd et a Candida albicans in				current Eschei	richia coli and			
/PP/	AX	Zhang et al., "Differe Journal of Clinical M	ential Blocking of Coa	agulation-Activating	Pathways of Li	mulus Amebo	cyte Lysate,"			
/PP/	AY	Casey et al., "Plasm	a Cytokine and Endo	otoxin Levels Correla			with the Sepsis			
/PP/	AZ	Syndrome," Annals of Internal Medicine, Vol. 119 (Issue 8), 771-778 (October 15, 1993).  Abstract of Oettinger et al., "The clinical significance of prostaglandins and thromboxane as mediators of septic shock," Journal of Molecular Medicine, Vol. 65 (No. 2), 61-68 (January 1987).								
Examiner	I	1 Sepuc Silver, Journ	ai di Mondoulai Moul	<u> </u>	, or oo loanua	Date Consid	dered			
*EXAMINER not in confor	: Initial i	f reference considered ind not considered. In	I, whether or not cita clude copy of this for	tion is in conformand m with next commun	e with MPEP ( nication to appl	609. Draw line icant.	through citation if			

BASED ON FORM PTO 1449

Sheet 2 of 2

				_					<u> </u>			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. 3220-69262				SERIAL No.: 10/044,031			
APPLICANT(S): Badylak et al.							al.					
INFORMATION DISCLOSURE STATEMENT					FILING DATE: January 11, 2002			GP	ROUP: 3738			
U.S. PATENT DOCUMENTS												
*Examiner Initial		Document Number	Date		Name	Class	Subclass	s '	Filing Date if Appropriate			
	BA											
	ВВ											
	вс											
	BD							$\neg$				
	BE							$\neg$				
	BF											
	BG								<del></del>			
	ВН							$\neg$				
	ВІ											
	BJ											
	ВК											
			FOREIGN	PAT	ENT DOCUMEN	πs						
		Document Number	Date		Country	Class	Subclass	s	Translation Yes No			
	BL											
	ВМ		·									
	BN						·					
	во			igsqcup								
	BP			<u></u>					····			
	<del></del>		ERENCES (Includia					<del></del>	<del></del> -			
/PP/	BR	Sauter et al., "Etic immunology, Ore	ology of Early Lifes agon Health Scienc	₃tage ces t	→ Diseases," Fina <i>Iniversity</i> .	il Report 1985,	Dept. of Micro	biolog <sub>)</sub>	y and			
	BS				<del>.</del>							
	BT											
	BU											
	BV											
	BW											
	BX											
	BY											
	BZ											
Examiner		Prebilic/ .						Date Considered 09/03/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

BASED ON FORM PTO 1449